Can-Fite BioPharma (CANF) AI Stock Analysis

• Market Cap: $15.62M
• Dividend Yield: N/A
• Average Volume (3M): 84.14K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.00
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 5
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 12,977,183
• 10 Day Avg. Volume: 52,779
• 30 Day Avg. Volume: 84,142
• PEG Ratio: -0.16
• Price to Book (P/B): 1.72
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.87
• Enterprise Value/Market Cap: 0.61
• Enterprise Value/Revenue: 3.55
• Enterprise Value/Gross Profit: 14.20
• Enterprise Value/Ebitda: -0.31
• 1Y Price Target: $4.50
• Price Target Upside: 305.41% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 42 Neutral
• Price Target: $1.00 ▼(-9.91%Downside)

Can-Fite BioPharma's overall stock score reflects significant financial challenges and a bearish technical outlook. The company's negative profitability, declining revenues, and reliance on external financing are major concerns. Technical indicators suggest caution, while valuation metrics indicate ongoing losses, affecting investor confidence.

Can-Fite BioPharma Business Overview & Revenue Model

Company Description

Can-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company based in Israel, focused on the development of small molecule therapeutics for the treatment of autoimmune inflammatory diseases, oncology, and liver health. The company leverages its proprietary platform technology to develop its pipeline of drug candidates, which includes Piclidenoson, Namodenoson, and CF602, targeting conditions such as psoriasis, rheumatoid arthritis, liver cancer, and erectile dysfunction.

How the Company Makes Money

Can-Fite BioPharma generates revenue primarily through licensing agreements and collaborations with pharmaceutical companies for the development and commercialization of its drug candidates. These agreements often include upfront payments, milestone payments based on the achievement of clinical, regulatory, and sales milestones, as well as royalties from product sales. The company also seeks to secure funding through public and private offerings of its securities to support its research and development activities. Significant partnerships and collaborations with other pharmaceutical companies and research institutions are key contributors to its earnings.

Can-Fite BioPharma Financial Statement Overview

Summary

Can-Fite BioPharma is facing significant financial challenges with declining revenues, persistent losses, and reliance on external financing. The income statement shows negative profitability margins and decreasing equity, while the cash flow statement indicates consistent negative free cash flow. Improvements in operational efficiency and revenue growth are crucial to strengthening the company's financial position.

Income Statement

Can-Fite BioPharma's income statement reveals significant challenges, with consistent negative EBIT and net income over the years, indicating ongoing operational inefficiencies. The company has experienced declining revenue, with a revenue decrease of approximately 9.3% from 2023 to 2024. Margins are negative, with a net profit margin of -1169% in 2024, highlighting profitability issues. Despite these challenges, the gross profit margin remains positive due to relatively low cost of goods sold.

Balance Sheet

The balance sheet shows a mixed picture. Can-Fite BioPharma maintains a low level of debt, with a debt-to-equity ratio of 0.019 in 2024, suggesting limited leverage risk. However, the stockholder's equity has been decreasing, indicating potential erosion in financial stability. The equity ratio stands at 59.6%, reflecting a moderate reliance on equity to finance assets. The decreasing equity may pose future risks if the trend continues.

Cash Flow

Cash flow analysis indicates consistent negative free cash flow, which is a concern for sustainability. However, the free cash flow has improved by 9.5% from 2023 to 2024. The operating cash flow to net income ratio is negative, indicating that operations are not generating sufficient cash to cover net losses. The company has relied on financing activities to sustain operations, as seen with substantial financing cash flow in recent years.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
674.00K	743.00K	810.00K	853.00K	763.00K
	Gross Profit
674.00K	743.00K	810.00K	853.00K	763.00K
	EBIT
-8.13M	-8.20M	-10.10M	-12.84M	-14.14M
	EBITDA
-8.12M	-8.18M	-10.08M	-12.83M	-14.13M
	Net Income Common Stockholders
-7.88M	-7.63M	-10.53M	-12.60M	-14.81M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
7.89M	8.92M	7.98M	19.14M	8.34M
	Total Assets
9.12M	9.99M	9.28M	20.25M	9.52M
	Total Debt
104.00K	40.00K	62.00K	124.00K	67.00K
	Net Debt
-4.72M	-4.24M	-2.92M	-4.27M	-8.20M
	Total Liabilities
3.68M	3.75M	4.81M	5.87M	3.45M
	Stockholders Equity
5.44M	6.24M	4.47M	14.38M	6.07M
Cash Flow		Free Cash Flow
-7.64M	-8.44M	-10.81M	-9.87M	-12.09M
	Operating Cash Flow
-7.64M	-8.44M	-10.80M	-9.86M	-12.06M
	Investing Cash Flow
1.50M	498.00K	9.50M	-14.51M	-26.00K
	Financing Cash Flow
6.71M	9.14M	0.00	20.46M	17.68M

Can-Fite BioPharma Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.11
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CANF, the sentiment is Neutral. The current price of 1.11 is above the 20-day moving average (MA) of 1.07, below the 50-day MA of 1.19, and below the 200-day MA of 1.72, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 49.59 is Neutral, neither overbought nor oversold. The STOCH value of 73.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CANF.

Can-Fite BioPharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$5.31B	3.26	-45.10%	2.79%	16.76%	0.02%
LPCN	48 Neutral	$16.96M	650.59	-24.89%	―	10081.34%	―
CING	47 Neutral	$18.51M	―	-358.06%	―	―	95.52%
CANF	42 Neutral	$15.62M	―	-122.28%	―	―	―
EQ	42 Neutral	$13.57M	―	-88.32%	―	-19.76%	-13.20%
EDSA	35 Underperform	$12.85M	―	-58.78%	―	―	-126.54%
UBX	31 Underperform	$11.72M	―	-231.27%	―	―	35.08%